JAK2 and non-small cell lung carcinoma: In NSCLC, loss-of-function JAK1 or JAK2 mutations have been identified in tumors refractory to PD-1 blockade, leading to impaired interferon-γ responsiveness and diminished CD8+ T-cell infiltration (35).